You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: April 2024 to January 2026

AbstractFullPdf
Apr 2024850858428
May 2024511516344
Jun 2024342342244
Jul 2024370370177
Aug 2024254253184
Sep 2024562563312
Oct 2024546552307
Nov 2024721726357
Dec 2024644654321
Jan 2025761763395
Feb 2025762764379
Mar 2025777782466
Apr 202510731078394
May 2025835835334
Jun 2025517521275
Jul 2025221
Sep 2025111
Jan 2026100
Total952995804919